Community-acquired methicillin-resistant Staphylococcus aureus (MRSA): new issues for infection control.
The emergence and clonal expansion of strains of community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) have created new challenges with their entrance to hospitals. The increased virulence of CA-MRSA in concert with the depressed immunity of inpatients may cause added morbidity and mortality expected from healthcare-associated infections. Questions about changing prophylactic and empirical therapy as well as the use of intravenous immunoglobulin for life-threatening infections are addressed.
Wenzel
Richard P
RP
Department of Internal Medicine, Medical College of Virginia Campus, Virginia Commonwealth University, and Medical College of Virginia Hospitals, 1101 East Broad Street, P.O. Box 980663, Richmond, VA 23298, USA. rwenzel@mcvh-vcu.edu
Bearman
Gonzalo
G
Edmond
Michael B
MB
D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000382:microbiology; D003428:Cross Infection / Q000188:drug therapy / Q000382:microbiology; D006801:Humans; D017053:Infection Control; D007956:Leukocidins / Q000235:genetics / Q000502:physiology; D016106:Methicillin Resistance; D013203:Staphylococcal Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects*
D007956:Leukocidins